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administration costs and $8,786 in AE costs. The cost per-patient for bortezomib SQ 
was $532,877, including $495,513 in drug costs, $30,906 in administration costs and 
$6,458 in AE costs. The model estimates that 10% of MM patients covered by public 
institutions are using bortezomib IV. If these patients switched to bortezomib SQ, 
total savings to a payer would be $3,803,850 ($120,258/patient, 18.4%), including 
$3,731,088 ($117,958/patient) in administration and $73,626 ($2,328/patient) in AE 
cost savings. ConClusions: The use of bortezomib SQ instead of IV could provide 
access to a highly efficacious therapy while conferring savings to Mexican public 
payers. Given non-inferior efficacy, migration from IV to SQ bortezomib results in 
improved tolerability and reduced administration requirements without reducing 
clinical benefits from treatment.
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objeCtives: Given the recent launch of generic bortezomib IV, payers may look to 
increase utilization of bortezomib IV to contain costs for the treatment of adults with 
relapsed/refractory MM in Venezuela. Prior to the introduction of bortezomib subcu-
taneous (SQ), bortezomib IV was the standard of care. This study evaluates the fiscal 
impact of increased use of generic bortezomib IV on total treatment costs. Methods: 
A budget impact model was developed from the Venezuelan public payer perspective. 
Resource costs were based on local provider interviews (2014 Venezuelan bolivars). 
Treatment dosing and AE rates were based on clinical trials. Inputs for market basket 
comparators, adverse event (AE) management and drug administration were esti-
mated via three clinician interviews. Generic bortezomib IV was assumed to be priced 
at 30% of the price of bortezomib SQ and market adoption was based on manufacturer 
projections, assuming equi-proportional migration from all comparators (combina-
tions including lenalidomide, thalidomide, melphalan and dexamethasone), except 
bortezomib SQ, which is constant. Cost of treatment is combined with literature-
based estimates for the adult prevalence of MM (0.0018%), cases that are relapsed/ 
refractory (52%), and likelihood of treatment (100%) to estimate annual costs for the 
full population. Results: The cost of treating 270 incident patients under current 
market shares is estimated at $27,699,084 ($102,510/patient). Assuming a 20% market 
share adoption of generic bortezomib IV, annual costs would increase by 26.2% to 
$34,944,197 ($129,323/patient), driven by the increased utilization of bortezomib IV 
($20,155/patient) relative to other regimens and increases in administration ($4,562/
patient) and AE costs ($2,096/patient). ConClusions: Increased utilization of generic 
bortezomib IV is not likely to translate into cost savings for the Venezuelan public 
payer given increased drug, AE and administration costs. Another option for lowering 
costs may be to promote the use of newer treatment alternatives that provide both 
high efficacy and favorable AE and administration profiles.
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objeCtives: Cancer incidence has increased in last decades. Meanwhile, new and 
costly intravenous chemotherapy drugs (CT) are added to current treatment options. 
Cost of chemotherapy is not restricted to drugs themselves, and some of the equip-
ment used for infusion can impact the final value. CT can be administered on simple 
IV lines although some require the use of pumps infusion sets (PIS) both of which 
may be PVC free or photosensitive depending on the drug. Nonetheless, several 
cancer centers in Brazil adopt CT pump infusion as a rule, despite manufacturers 
instructions. We aim to assess the added cost of unnecessary PIS use during CT infu-
sion. Methods: In this cost-minimization study we compared 2 scenarios: use of PIS 
according to manufacturer recommendations or as a rule for all CT. Chemotherapy 
treatments for breast cancer (AC-T, AC-TH, TAC, FAC, CMF and FEC100), lung cancer 
(carboplatin/paclitaxel with and without bevacizumab, vinorelbine/cisplatin, cispl-
atin/paclitaxel and pemetrexed/cisplatin) and colon cancer (fluorouracil/leucovorin, 
FOLFIRI, FOLFOX, cetuximab/irinotecan) were listed from the Brazilian Society of 
Clinical Oncology (SBOC) manual. Minimum, mean and maximal costs for drugs and 
equipment were retrieved from the official price list (SIMPRO), daily cost of infusion 
and increment in cost were also calculated in Brazilian Reais (R$). Results: Fifteen 
CT combinations were evaluated (6 for breast, 5 for colon and 4 for lung cancer). For 
breast cancer, the mean incremental cost per day of infusion with PIS varied from 
R$ 994.35 to R$ 1,839.54, depending on the chemotherapy scheme used. For lung 
cancer these values varied from R$ 356.34 a R$ 1,201.53 and for colon cancer treat-
ment the incremental cost was R$ 1,226.36. ConClusions: Although medications 
are the main source of expense in cancer treatment, unnecessary use of PIS can 
add considerable costs to chemotherapy and correct use according to manufacturer 
recommendation should be reinforced.
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The clinical benefit of stapled anastomosis creation of right colon resection surgery 
is expected to be accompanied by a strong potential economic benefit – as estimated 
for hospitals in Brazil.
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objeCtivos: estimar el costo por año de vida y años de vida ajustados por cali-
dad en pacientes con carcinoma basocelular localmente avanzado, tratados con 
vismodegib frente a tratarlos con radioterapia secundaria. MetodologíAs: se 
diseñó un modelo de Markov, con un horizonte temporal hasta la muerte, bajo 
ciclos semanales, que simula la historia natural de pacientes adultos con carci-
noma basocelular localmente avanzado, inapropiados para cirugía. Se utilizaron 
tres estados de salud: libres de progresión, progresión y muerte; utilizando réplicas 
de curvas de eventos de Kaplan-Meier, tanto para progresión como para sobrevida. 
Las probabilidades requeridas para la estimación del modelo fueron estimadas de 
los estudios ERIVANCE y STEVIE. Como desenlaces se utilizaron los años de vida 
ajustados por calidad y costos totales. Los costos de servicios fueron extraídos de 
bases de datos venezolanas, mientras que los de medicamentos fueron estimados 
con fuente del Ministerio del Poder Popular para la Salud. Además, se utilizó una tasa 
de descuento del 5% para costos y resultados. Por último, se realizó un análisis de 
sensibilidad tipo Montecarlo. ResultAdos: los años de vida, los años ajustados por 
calidad y el costo medio (en bolívares fuertes) de un paciente localmente avanzado, 
tratado con vismodegib fue de 6,55, 4,77 y $1.210.554 respectivamente, mientras 
que con radioterapia fue de 6,44, 4,45 y $628.908. Por ende, vismodegib tiene una 
mejor eficacia, lo cual se refleja en más del 86 % de las iteraciones en el análisis 
de sensibilidad. ConClusiones: vismodegib es dominante frente a radioterapia 
secundaria en eficacia, bajo el desenlace de años de vida ajustados por calidad. 
Su costo medio de uso anual es de $184.636, lo cual representa un impacto bajo, 
dada una prevalencia baja de 3,3 por 100.000 y solo del 5% en estadios avanzados.
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objeCtives: Multiple Myeloma (MM) is a hematological malignancy characterized 
by skeletal destruction, renal failure, anemia and hypercalcemia. Only 4 to 5% of 
the patients experience a survival of more than 10 years. The incidence reported 
worldwide was 114,251 new cases per year, with 1.5 cases per 100,000 residents. 
Given its low incidence, MM is considered orphan disease. The objective of the study 
is to estimate the budget impact to the Mexican public healthcare system when 
introducing Carfilzomib in the treatment of patients with refractory and relapsed 
MM who have received at least two previous treatments, including bortezomib and 
an immunomodulating agent. Methods: A budget impact analysis was conducted 
using a 3 health states Markov model (progression-free, post-progression and death) 
with monthly cycle length. The budget impact of Carfilzomib was compared to the 
current standard treatment in Mexico (high-dose dexamethasone), while low-dose 
dexamethasone was assumed after progression, according to Mexican KOLs advice. 
The eligible population was based on the incidence rate (3/100,000) for MM in Mexico 
and an estimate of the percentage of relapsed and refractory patients from the 
literature. Only direct medical costs were accounted for drugs, procedures, labora-
tory tests and adverse events management. Costs were expressed in US dollars 
(Exchange rate $15.16/USD) Results: After introducing Carfilzomib, incremental 
budget impact in the first 5 years wasestimated to have an average budget increase 
of .0033%. ConClusions: Assuming an increasing uptake of 5% per year, introduc-
ing Carfilzomib to the Mexican public healthcare system would on average increase 
budget by 0.0033%, being affordable in terms of funding and representing an effec-
tive and safe new therapeutic option for patients with relapsed and refractory MM.
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objeCtives: To conduct an exploratory analysis on the budgetary impact of migra-
tion from bortezomib IV to bortezomib SQ for the treatment of adults with relapsed/
refractory MM in Mexico. Methods: A budget impact model was developed using 
Microsoft Excel 2007® from the Mexican public payer perspective. Interviews with 
three clinicians (IMSS, INCAN, ISSSTE) currently treating relapsed/refractory MM 
patients were used to derive inputs for market shares, market basket compara-
tors, grade 3 and 4 adverse event (AE) management (anemia, thrombocytopenia, 
peripheral neuropathy, neutropenia, fatigue, pneumonia and infection) and practice 
patterns for drug administration. Treatment dosing and AE rates were based on a 
clinical trial comparing bortezomib SQ and bortezomib IV. Unit costs for healthcare 
resources and drugs reflect published IMSS rates (2015 Mexican pesos). Cost of 
treatment is combined with literature-based estimates for the adult prevalence 
of MM (0.0018%), population covered by public institutions (39%), cases that are 
relapsed/refractory (52%), and likelihood of bortezomib IV treatment (10%) to esti-
mate annual costs for this population. Results: The annual per-patient treatment 
cost for bortezomib IV was $653,136, including $495,486 in drug costs, $148,864 in 
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objeCtives: Assess the relative clinical and economic value of Ipilimumab as 
second-line treatment of metastatic melanoma compared with other metastatic 
cancers agents in Brazil. Methods: A literature review of clinical data supporting 
approval of various metastatic cancers agents meeting the following criteria: market 
and price approval in Brazil within the last 10 years, OS as primary/secondary end-
points in clinical trials, median OS at time of regulatory approval and availability of 
Kaplan-Meier OS curves, was conducted. The studies selected provided data to ana-
lyze changes in median/mean OS, on 1-year survival rate in absolute (i.e. months) 
and relative (i.e. percent of improvement) terms and NNT at 1 year to avoid one 
death. Clinical outcomes were associated with drug costs, which were obtained from 
the official Brazilian price list issued on 20/Jan/2015 by CMED. Results: Relative to 
other agents, ipilimumab demonstrated absolute improvement in mean OS of 6.1 
months (versus 0.1-6.4 months), a relative improvement in mean OS of 53% (versus 
1.3-34.3%), absolute improvement in median OS of 3.7 months versus 0-13.3 months 
(76,92% were ≤ 4 months with other agents), relative improvement in median OS 
of 57.8% (vs 0-63.3%), absolute improvement in 1-year survival rate (20.3% versus 
0-15.0%), relative improvement in 1-year survival rate (80.2% versus 4.2-81.5%) and 
the lowest NNT at 1 year to avoid 1 death (5 patients versus 6.47–31.5 patients). 
Ipilimumab’s relative value was confirmed when plotting each drug’s clinical per-
formance vs total drug costs. ConClusions: Results document that second-line 
ipilimumab demonstrates relative median OS and absolute mean OS improvements. 
Ipilimumab achieved the greatest relative mean OS improvement, absolute 1-year 
survival rate improvement and the lowest NNT at 1 year. Comparative analysis 
demonstrates the clinical and economic value of Ipilumumab. This analysis pro-
vides health-care decision makers another tool in their decision making process.
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objeCtivos: Estimar los costos del Cáncer de Mama (CMA) en los establecimien-
tos del Ministerio de Salud del Perú. MetodologíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes con CMA afiliados al Seguro Público de Salud 
(Seguro Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva 
del financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratamiento y 
seguimiento de la enfermedad) provienen de las Condiciones Asegurables del Plan 
Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo clínico se 
ha estimado con la metodología de costeo estándar. El costo total fue ajustado por 
factores de oferta, demanda y adherencia. ResultAdos: La cohorte hipotética de 
CMA es de 658 personas para el año 2014 (Incidencia de CMA temprano en Perú: 
29 x 100,000 y de CMA localmente avanzado: 13 x 100,000). El costo total para CMA 
es de 36,245,142 dólares correspondiendo a CMA temprano: 29,642,129 dólares y 
para CMA localmente avanzado: 6,603,013 dólares. El costo total correspondiente a 
prevención es de 24,068 dólares (0.1%), diagnóstico 109,706 dólares (0.3%), tratami-
ento 36,032,944 dólares (99.4%) y para seguimiento 78,424 dólares (0.2%). El costo 
fijo correspondió a 6,838,797 dólares (18.9%) y el costo variable a 29,406,345 dólares 
(81.1%). ConClusiones: El costo anual total para Cáncer de Mama en el Perú se 
estimó en 36,245,142 dólares. Este monto representa el 19.6% del presupuesto anual 
en el programa presupuestal de prevención y control del cáncer del país.
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objeCtivos: Estimar los costos del Cáncer de Próstata (CP) en los establecimien-
tos del Ministerio de Salud del Perú. MetodologíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes con CP afiliados al Seguro Público de Salud 
(Seguro Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva 
del financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratamiento y 
seguimiento de la enfermedad) provienen de las Condiciones Asegurables del Plan 
Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo clínico se 
ha estimado con la metodología de costeo estándar. El costo total fue ajustado por 
factores de oferta, demanda y adherencia. ResultAdos: La cohorte hipotética de 
CP es de 1,167 personas para el año 2014 (Incidencia de CP: 51 x 100,000). El costo 
total para CP es de 4,902,659 dólares correspondiendo a CP Estadio I: 437,084 dólares, 
CP Estadio II: 4,051,303 dólares y Estadio III: 414,273. El costo total correspondiente 
a diagnóstico es de 296,583 dólares (6.0%), tratamiento 4,536,335 dólares (92.5%) y 
para seguimiento 69,742 dólares (1.4%). El costo fijo correspondió a 4,140,073 dólares 
(84.4%) y el costo variable a 762,587 dólares (15.6%). ConClusiones: El costo anual 
total para Cáncer de Próstata en el Perú se estimó en 4,902,659 dólares. Este monto 
representa el 2.6% del presupuesto anual en el programa presupuestal de prevención 
y control del cáncer del país.
objeCtives: To determine the cost-effectiveness of Ben-R versus R-CHOP for the 
first-line treatment of patients with iNHL in Colombia. Methods: An economic 
model was constructed from the Colombian public payer perspective, with a life-
time horizon and discount rate of 5%. The model included three health states: 
progression-free (PF), progressive disease (PD) and death. Clinical inputs and PFS 
information were based on phase 3 clinical data. Overall survival (OS) data was 
not mature at the time of publication and the model conservatively assumes 
non-differential survival, estimated by disease-related mortality adjustments 
applied to all-cause mortality rates in Colombia. Therefore, the analysis focused 
on progression-free life year (PFLY) outcomes as the most relevant measure of 
incremental treatment effect. Treatment patterns for 1st and 2ndline chemo-
therapy and resource use for disease monitoring and adverse event manage-
ment were based on the expert input of a Colombian hematologist. Unit costs 
(reported in 2014 Colombian Pesos) were estimated via EPS manager interviews 
and SISMED published rates. Results: The total lifetime cost per iNHL patient 
was $292,962,824 for Ben-R and $249,522,769 for R-CHOP. Total life years were 
7.80 for both arms but Ben-R demonstrated gains in QALYs (5.86 vs. 5.49) and 
PFLYs (5.58 vs. 3.62) over R-CHOP given improvements in PFS. The ICER per PFLY 
of $22,091,813 demonstrates that the use of Ben-R is cost effective, as the ICER 
falls below the willingness to pay (WTP) of Colombia at three times the GDP per 
capita ($44,788,404). Univariate sensitivity analysis revealed that the ICER per 
PFLY was most sensitive to the hazard ratio for PFS, number of Ben-R treatment 
cycles and the discount rate for outcomes. Probabilistic sensitivity analysis esti-
mated that Ben-R had an 88% chance of being cost-effective based on current WTP 
thresholds. ConClusions: Ben-R is a cost-effective alternative to R-CHOP for the 
first-line treatment of iNHL in Colombia.
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objeCtives: To calculate the distribution among treatment related average costs 
of the use of TKI’s versus the combination of pemetrexed/cisplatin in relation to 
four core cost items: Acquisition, application, medical care and disease progres-
sion. Methods: A discrete event simulation cost-effectiveness model with one 
month cycles (progression free, disease progression and death) assessed treatment 
related costs in a five year horizon until death. Average costs for TKIs where taken 
from three different therapies: afatinib, erlotinib and gefitinib. Public institutional 
direct medical costs (2014 purchases and price tabulators) were retrieved to adopt 
the national health system perspective. Efficacy inputs where obtained from a net-
work meta-analysis. Information gaps related to the use and frequency of medical 
resources where fulfilled with the results of a Delphi panel (10 oncologists of all 
major public institutions). The distribution among core cost items was calculated 
and later compared to obtain its share from the total treatment cost. Results: In 
the studied time horizon, the highest cost of treatment was reported by pemetrexed/
cisplatin with US$175,563, followed by a TKI mean of US$124,005. Disease progres-
sion cost was the most expensive item among alternatives, with US$154,025 and a 
mean of US$85,240.88 for pemetrexed/cisplatin and the TKIs respectively. Cost dis-
tribution among acquisition, application, medical care and disease progression cost 
for the TKIs average was 19%, 0%, 12% and 69% respectively. Pemetrexed/cisplatin 
cost distribution was 5%, 2%, 5% and 88% at the same core items. ConClusions: 
The economic burden in the treatment of NSCLC with EGFR mutation is heavily 
weighted in the disease progression cost. Even though pemetrexed/cisplatin has 
the lowest drug acquisition cost, it has the most expensive cost of treatment as a 
whole. A drug acquisition investment in TKIs is worth paying as its cost of treatment 
was estimated to be lower in a five year horizon.
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objeCtives: To compare the cost of treatment of selected cancers with patented 
drugs: India versus neighboring countries. Methods: Patented anticancer drugs 
(expiring in/after 2016) were selected using USFDA Orange-Book. These drugs were 
further, screened at the Indian national regulatory database for their marketing 
approval status in the country. The price of these drugs was calculated using CIMS 
– India online. Indication and dose as approved by USFDA for CML and Advance 
Breast Cancer were considered to estimate the cost of therapy. The STGs recom-
mended by cancer.org were used. Results: Twelve patented anticancer drugs are 
approved for marketing in India. Of these, we note that 4 are not available in the 
Indian market (Crizotinib, Ruxolitinib, Degarelix & Vemurafenib); and, the patent of 
3 has been challenged (Sorafenib, Dasatinib & Fulvestrant). Lapatinib is approved for 
treatment of CML while Nilotinib, Ixabepilone & Eribulin are for different stages of 
Breast Cancer. The cost of treatment of CML using Lapatinib is $8000/year in India; 
and, this is $18000, $17000, $17000 & $7000 for Philippines, Malaysia, Pakistan & 
Indonesia, respectively. Likewise, the cost of treatment of Advanced Breast Cancer 
using Nilotinib is $3000/year in India while $67000, $54000, $38000 & $4000 for 
Malaysia, Pakistan, Indonesia & Philippines, respectively. The costs are rounded. 
Though it is not meaningful to compare these costs with American costs; CML treat-
ment costs $51000/year while for Advance Breast Cancer treatment costs $1,20,000/
year. ConClusions: In India, the cost of treatment of CML is approximately half 
when compared to most of the neighboring countries. For Advanced Breast Cancer, 
the costs are 12-22 times lower on similar comparison.
